← Back to Investor Relations
In the Press
How Investors May Respond to Quest's Blood-Based Cancer Screening
Why This Matters
SAHM Capital serves Middle Eastern and international investment communities. This syndication of the Simply Wall St. analysis extends Helio Genomics' visibility to international investors evaluating the cancer diagnostics market.
Article Summary
SAHM Capital syndicates the Simply Wall St. analysis examining how Quest Diagnostics' partnerships with Helio Genomics and Guardant Health to distribute blood-based cancer screening tests will impact investor returns. The article frames these partnerships as additive to Quest's growth narrative around higher-margin advanced oncology testing, with projected 2028 revenue of $11.9 billion.